Novo Nordisk CEO: Still no capacity for large-scale M&A

1. 1Novo Nordisk (NVO) CEO Doustdar reiterated on the Q2 earnings call that a large-scale, transformative acquisition remains distant
2. 2The Bolt-on acquisition is being actively pursued, while Akero Therapeutics was acquired for $5.2 billion in October 2025
3. 3With mixed pipeline clinical results and sluggish demand for the Wegovy pill, narrowing the gap with Eli Lilly (LLY) remains a difficult task

Source The Wall Street Journal +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →